Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 2/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | SCN1A | P35498 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6458666 | 0.83 | ITGB2 (0.41) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL7471891 | 0.77 | CHRNB4 (0.43) | CHRNB4CHRNA3CHRNB2CHRNA4NISCH | |
| SCHEMBL1898922 | 0.74 | — | — | |
| SCHEMBL11305978 | 0.74 | CHRNB4 (0.53) | CHRNB4CHRNA3CHRNB2CHRNA4NISCH | |
| SCHEMBL9774593 | 0.74 | CHRNB4 (0.53) | CHRNB4CHRNA3CHRNB2CHRNA4NISCH | |
| SCHEMBL7441397 | 0.74 | CHRNB4 (0.53) | CHRNB4CHRNA3CHRNB2CHRNA4NISCH | |
| SCHEMBL11046521 | 0.74 | CHRNB4 (0.53) | CHRNB4CHRNA3CHRNB2CHRNA4NISCH | |
| SCHEMBL11291799 | 0.74 | CHRNB4 (0.53) | CHRNB4CHRNA3CHRNB2CHRNA4NISCH | |
| SCHEMBL11305709 | 0.74 | CHRNB4 (0.53) | CHRNB4CHRNA3CHRNB2CHRNA4NISCH | |
| SCHEMBL18374091 | 0.72 | CHRNB4 (0.56) | CHRNB4CHRNA3CHRNB2CHRNA4NISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601745-B2 | Heterocyclic NF-kB inhibitors | 4SC AG (DE) | 2009-10-13 | — | — | US | disclosed |
| US-20060247253-A1 | Novel heterocyclic NF-kB inhibitors | 4 SC AG (DE) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247253-A1 | Novel heterocyclic NF-kB inhibitors | NFKBIA, NFRKB, NFKB2 | CHRNB4 173/4885CHRNA3 287/4885CHRNB2 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.